Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial

Sonja Zweegman; Claudia A M Stege; Einar Haukas; Fredrik H Schjesvold; Mark-David Levin; Anders Waage; Rineke B L Leys; Saskia K Klein; Damian Szatkowski; Per Axelsson; Trung Hieu Do; Dorota Knut-Bojanowska; Ellen van der Spek; Asta Svirskaite; Anja Klostergaard; Morten Salomo; Celine Blimark; Paula F Ypma; Ulf-Henrik Mellqvist; Pino J Poddighe; Marian Stevens-Kroef; Niels W C J van de Donk; Pieter Sonneveld; Markus Hansson; Bronno van der Holt; Niels Abildgaard

doi:10.3324/haematol.2019.240374

Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial

Sonja Zweegman, Claudia A M Stege, Einar Haukas, Fredrik H Schjesvold, Mark-David Levin, Anders Waage, Rineke B L Leys, Saskia K Klein, Damian Szatkowski, Per Axelsson, Trung Hieu Do, Dorota Knut-Bojanowska, Ellen van der Spek, Asta Svirskaite, Anja Klostergaard, Morten Salomo, Celine Blimark, Paula F Ypma, Ulf-Henrik Mellqvist, Pino J PoddigheMarian Stevens-Kroef, Niels W C J van de Donk, Pieter Sonneveld, Markus Hansson, Bronno van der Holt, Niels Abildgaard

Onderzoeksoutput › Academic › peer review

25 Citaten (Scopus)

21 Downloads (Pure)

Originele taal-2	English
Pagina's (van-tot)	2879-2882
Aantal pagina's	4
Tijdschrift	Haematologica
Volume	105
Nummer van het tijdschrift	12
DOI's	https://doi.org/10.3324/haematol.2019.240374
Status	Published - 1-dec.-2020
Extern gepubliceerd	Ja

Toegang tot document

10.3324/haematol.2019.240374Licentie: CC BY-NC

Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trialFinal publisher's version, 436 KBLicentie: CC BY-NC

Handle.net

Permanente koppeling

Citeer dit

Zweegman, S., Stege, C. A. M., Haukas, E., Schjesvold, F. H., Levin, M.-D., Waage, A., Leys, R. B. L., Klein, S. K., Szatkowski, D., Axelsson, P., Hieu Do, T., Knut-Bojanowska, D., van der Spek, E., Svirskaite, A., Klostergaard, A., Salomo, M., Blimark, C., Ypma, P. F., Mellqvist, U.-H., ... Abildgaard, N. (2020). Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial. Haematologica, 105(12), 2879-2882. https://doi.org/10.3324/haematol.2019.240374

Zweegman, Sonja ; Stege, Claudia A M ; Haukas, Einar et al. / Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial. In: Haematologica. 2020 ; Vol. 105, Nr. 12. blz. 2879-2882.

@article{f3f7db9f127946dfa76105b10af58484,

title = "Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial",

keywords = "Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Boron Compounds, Bortezomib/therapeutic use, Dexamethasone/therapeutic use, Glycine/analogs & derivatives, Hematopoietic Stem Cell Transplantation, Humans, Multiple Myeloma/diagnosis, Stem Cell Transplantation, Thalidomide/therapeutic use, Transplantation, Autologous, Treatment Outcome",

author = "Sonja Zweegman and Stege, {Claudia A M} and Einar Haukas and Schjesvold, {Fredrik H} and Mark-David Levin and Anders Waage and Leys, {Rineke B L} and Klein, {Saskia K} and Damian Szatkowski and Per Axelsson and {Hieu Do}, Trung and Dorota Knut-Bojanowska and {van der Spek}, Ellen and Asta Svirskaite and Anja Klostergaard and Morten Salomo and Celine Blimark and Ypma, {Paula F} and Ulf-Henrik Mellqvist and Poddighe, {Pino J} and Marian Stevens-Kroef and {van de Donk}, {Niels W C J} and Pieter Sonneveld and Markus Hansson and {van der Holt}, Bronno and Niels Abildgaard",

year = "2020",

month = dec,

day = "1",

doi = "10.3324/haematol.2019.240374",

language = "English",

volume = "105",

pages = "2879--2882",

journal = "Haematologica",

issn = "0390-6078",

publisher = "FERRATA STORTI FOUNDATION",

number = "12",

}

Zweegman, S, Stege, CAM, Haukas, E, Schjesvold, FH, Levin, M-D, Waage, A, Leys, RBL, Klein, SK, Szatkowski, D, Axelsson, P, Hieu Do, T, Knut-Bojanowska, D, van der Spek, E, Svirskaite, A, Klostergaard, A, Salomo, M, Blimark, C, Ypma, PF, Mellqvist, U-H, Poddighe, PJ, Stevens-Kroef, M, van de Donk, NWCJ, Sonneveld, P, Hansson, M, van der Holt, B & Abildgaard, N 2020, 'Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial', Haematologica, vol. 105, nr. 12, blz. 2879-2882. https://doi.org/10.3324/haematol.2019.240374

Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial. / Zweegman, Sonja; Stege, Claudia A M; Haukas, Einar et al.
In: Haematologica, Vol. 105, Nr. 12, 01.12.2020, blz. 2879-2882.

Onderzoeksoutput › Academic › peer review

TY - JOUR

T1 - Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial

AU - Zweegman, Sonja

AU - Stege, Claudia A M

AU - Haukas, Einar

AU - Schjesvold, Fredrik H

AU - Levin, Mark-David

AU - Waage, Anders

AU - Leys, Rineke B L

AU - Klein, Saskia K

AU - Szatkowski, Damian

AU - Axelsson, Per

AU - Hieu Do, Trung

AU - Knut-Bojanowska, Dorota

AU - van der Spek, Ellen

AU - Svirskaite, Asta

AU - Klostergaard, Anja

AU - Salomo, Morten

AU - Blimark, Celine

AU - Ypma, Paula F

AU - Mellqvist, Ulf-Henrik

AU - Poddighe, Pino J

AU - Stevens-Kroef, Marian

AU - van de Donk, Niels W C J

AU - Sonneveld, Pieter

AU - Hansson, Markus

AU - van der Holt, Bronno

AU - Abildgaard, Niels

PY - 2020/12/1

Y1 - 2020/12/1

KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use

KW - Boron Compounds

KW - Bortezomib/therapeutic use

KW - Dexamethasone/therapeutic use

KW - Glycine/analogs & derivatives

KW - Hematopoietic Stem Cell Transplantation

KW - Humans

KW - Multiple Myeloma/diagnosis

KW - Stem Cell Transplantation

KW - Thalidomide/therapeutic use

KW - Transplantation, Autologous

KW - Treatment Outcome

U2 - 10.3324/haematol.2019.240374

DO - 10.3324/haematol.2019.240374

M3 - Comment/Letter to the editor

C2 - 33256392

SN - 0390-6078

VL - 105

SP - 2879

EP - 2882

JO - Haematologica

JF - Haematologica

IS - 12

ER -

Zweegman S, Stege CAM, Haukas E, Schjesvold FH, Levin MD, Waage A et al. Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial. Haematologica. 2020 dec. 1;105(12):2879-2882. doi: 10.3324/haematol.2019.240374